IBD Treatment Insurance Denied? How to Appeal

Inflammatory bowel disease — including Crohn's disease and ulcerative colitis — affects approximately 3.1 million Americans and requires long-term, often expensive treatment. When insurance denies biologic therapy such as infliximab (Remicade), vedolizumab (Entyvio), or ustekinumab (Stelara), patients face a critical choice: pay tens of thousands of dollars out of pocket or go without treatment that prevents disease progression and hospitalization. Appeals work — and this guide shows you how.

Why Insurers Deny IBD Treatment

Step therapy requirements. Insurers require patients to fail older medications (aminosalicylates, corticosteroids, azathioprine, 6-mercaptopurine) before approving biologics. Even when your gastroenterologist recommends a biologic upfront for moderate-to-severe disease, the insurer may insist on an often futile sequence of cheaper drugs first. The 21st Century Cures Act (2016) and most state step therapy laws create a formal exception process when step therapy would be medically harmful or has already failed.

Not medically necessary. The insurer's utilization reviewer applies internal clinical criteria that may not align with current American Gastroenterological Association (AGA) guidelines. The AGA recommends biologic therapy for patients with moderate-to-severe IBD, frequent flares, steroid dependence, or disease refractory to conventional therapy.

Biologic not on formulary or not preferred. If a biosimilar is preferred over the originator biologic, or one biologic is preferred over another, a formulary exception is required. Physicians can document clinical reasons the preferred agent is inappropriate — prior adverse reactions, demonstrated loss of response, or disease features favoring a specific mechanism of action.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization expired or not obtained. All biologic IBD therapies require prior authorization, typically renewed every 6–12 months. An administrative failure to renew on time can trigger denial for an ongoing, approved course of treatment.

Hospitalization or procedure denied. Inpatient admission for severe flares, colectomy, or fecal microbiota transplantation may be denied as not meeting medical necessity criteria despite clinical urgency.

How to Appeal an IBD Denial

Step 1: Request the clinical policy bulletin

Ask the insurer in writing for the Clinical Policy Bulletin (CPB) or coverage determination used to evaluate your claim. This document specifies exact criteria and becomes your roadmap for the appeal.

Step 2: Document disease severity comprehensively

Compile disease activity scores (Harvey-Bradshaw Index or CDAI for Crohn's; Mayo Score or Simple Clinical Colitis Activity Index for UC), colonoscopy findings with histopathology, CRP and fecal calprotectin trends, and imaging results. Moderate-to-severe documented disease is the clinical foundation of your appeal.

Step 3: Obtain your gastroenterologist's letter addressing denial criteria

The letter must specifically respond to the insurer's stated denial reason. For step therapy denials, it should document each step therapy trial with dates, dosages, response, and reason for discontinuation. For medical necessity denials, it should cite AGA Clinical Practice Guidelines and the Crohn's and Colitis Foundation's current treatment recommendations.

Step 4: Invoke step therapy override rights if applicable

Under the 21st Century Cures Act and applicable state law, submit a formal step therapy exception request documenting that: (1) the required step therapy is contraindicated or clinically inappropriate for your presentation; (2) you have already tried and failed the required agents; or (3) the step therapy would cause clinically significant harm or disease progression.

Step 5: Request a peer-to-peer review

Ask your gastroenterologist to schedule a peer-to-peer call with the insurer's medical director. This direct clinical conversation resolves many IBD biologic denials efficiently, particularly when the insurer's reviewer has not reviewed your complete disease history.

Step 6: File for External Independent Review: Complete Guide" class="auto-link">external review

If the internal appeal fails, you have the right to independent external review at no cost under the ACA. Submit all documentation — clinical guidelines, disease activity scores, prior treatment records — to give the independent reviewer a complete picture. File a simultaneous complaint with your state department of insurance.

What to Include in Your Appeal

• Colonoscopy reports with histopathology documenting disease extent, severity, and activity grade
• Disease activity scores (CDAI, Harvey-Bradshaw, Mayo Score, or SCCAI)
• Inflammatory biomarkers (CRP, ESR, fecal calprotectin) showing active disease
• Prior treatment documentation with dates, dosages, duration, and specific reasons for failure or discontinuation of each agent
• Gastroenterologist letter citing AGA Guidelines and Crohn's and Colitis Foundation treatment algorithms
• FDA approval and package insert for the specific biologic and indication

Fight Back With ClaimBack

IBD biologic denials require appeals that document disease severity, prior treatment failures, and the clinical rationale for the specific agent prescribed. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal